The outlook of companies tied to Viagra's legacy presents a challenging investment landscape. While the initial success generated substantial returns , generic alternatives have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a careful assessment of proprietary protection , evolving medical changes, and the